Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Silodosin

FDA-approved product (capsule, oral), marketed as Rapaflo, Silodosin.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Silodosin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
FDA pharmacologic class
alpha-Adrenergic Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Silodosin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Silodosin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Multicenter Randomized Cross-Over Study Evaluating the Efficacy and Safety of Silodosin in Adult Women With Voiding Dysfunction

    NCT07822113 · start 2026-10

    Registered record
    Registry ID
    NCT07822113
    Conditions
    Voiding Dysfunction; Female LUTS
    Interventions
    Silodosin 8 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2027-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVoiding Dysfunction; Female LUTS
    InterventionSilodosin 8 mg; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients

    NCT07743034 · start 2026-08

    Registered record
    Registry ID
    NCT07743034
    Conditions
    Benign Prostatic Hyperplasia; Tamsulosin; Silodosin; Intraoperative Floppy Iris Syndrome; Tomography, Optical Coherence; Iris Diseases
    Interventions
    tamsulosin 0.4mg; Silodosin 8 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08
    Completion
    2027-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia; Tamsulosin; Silodosin; Intraoperative Floppy Iris Syndrome +2 more
    Interventiontamsulosin 0.4mg; Silodosin 8 mg
    PhasePhase 4
    Registry statusNot yet recruiting

  • Pupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients

    NCT07743060 · start 2026-08

    Registered record
    Registry ID
    NCT07743060
    Conditions
    Benign Prostatic Hyperplasia; Silodosin; Tamsulosin; Choroid; Iris Disease; Tomography, Optical Coherence
    Interventions
    tamsulosin 0.4mg; Silodosin 8 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08
    Completion
    2027-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia; Silodosin; Tamsulosin; Choroid +2 more
    Interventiontamsulosin 0.4mg; Silodosin 8 mg
    PhasePhase 4
    Registry statusNot yet recruiting

  • Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention

    NCT07650968 · start 2026-06-08

    Registered record
    Registry ID
    NCT07650968
    Conditions
    Acute Urinary Retention; Benign Prostatic Hyperplasia
    Interventions
    Tamsulosin 0.4 mg; Tamsulosin 0.8 mg; Silodosin 8 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-06-08
    Completion
    2027-06
    Enrolment
    378

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Urinary Retention; Benign Prostatic Hyperplasia
    InterventionTamsulosin 0.4 mg; Tamsulosin 0.8 mg; Silodosin 8 mg
    PhasePhase 4
    Registry statusRecruiting

  • Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

    NCT07614321 · start 2026-04

    Registered record
    Registry ID
    NCT07614321
    Conditions
    Multiple Sclerosis; Lower Urinary Track Symptoms
    Interventions
    Silodosin 8 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-04
    Completion
    2028-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis; Lower Urinary Track Symptoms
    InterventionSilodosin 8 mg; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial

    NCT07467343 · start 2026-03-22

    Registered record
    Registry ID
    NCT07467343
    Conditions
    Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms
    Interventions
    Silodosin; Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-03-22
    Completion
    2026-10-22
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia; Lower Urinary Tract Symptoms
    InterventionSilodosin; Tamsulosin
    PhasePhase 4
    Registry statusNot yet recruiting

  • Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction

    NCT07815379 · start 2025-10-12

    Registered record
    Registry ID
    NCT07815379
    Conditions
    BPH (Benign Prostatic Hyperplasia)
    Interventions
    alpha blocker monotherapy Tamsulosin; alpha blockers Tamsulosin and Silodosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2025-10-12
    Completion
    2026-11
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBPH (Benign Prostatic Hyperplasia)
    Interventionalpha blocker monotherapy Tamsulosin; alpha blockers Tamsulosin and Silodosin
    PhasePhase 4
    Registry statusActive not recruiting

  • Sildosin as a Male Contraceptive Non Hormonal

    NCT07195097 · start 2025-09

    Registered record
    Registry ID
    NCT07195097
    Conditions
    Contraception Use
    Interventions
    Oral intake of sildosin; Oral intake of placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2025-09
    Completion
    2025-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception Use
    InterventionOral intake of sildosin; Oral intake of placebo
    PhasePhase 1
    Registry statusNot yet recruiting

  • Clinical Outcomes and Ejaculatory Function in BPO Patients Treated With Silodosin

    NCT06989515 · start 2025-06-15

    Registered record
    Registry ID
    NCT06989515
    Conditions
    Benign Prostate Obstruction (BPO); Lower Urinary Tract Symptom; Ejaculatory Dysfunction; Anejaculation; Silodosin
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-06-15
    Completion
    2026-06-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostate Obstruction (BPO); Lower Urinary Tract Symptom; Ejaculatory Dysfunction; Anejaculation +1 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Silodosin in Facilitating Flexible Uretroscopy

    NCT07068087 · start 2025-02-01

    Registered record
    Registry ID
    NCT07068087
    Conditions
    Stone Ureter; Stone, Kidney
    Interventions
    Preoperative sioldosin to facilitate ureteric access sheath insertion in RIRS; ureteric access sheath insertion in RIRS without silodosin (Placebo)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2025-02-01
    Completion
    2025-09-01
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStone Ureter; Stone, Kidney
    InterventionPreoperative sioldosin to facilitate ureteric access sheath insertion in RIRS; ureteric access sheath insertion in RIRS without silodosin (Placebo)
    PhaseNot applicable
    Registry statusActive not recruiting

  • Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi

    NCT05977647 · start 2024-09-01

    Registered record
    Registry ID
    NCT05977647
    Conditions
    Ureteric Stone of Lower Third of Ureter
    Interventions
    Tamsulosin Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-09-01
    Completion
    2025-06-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUreteric Stone of Lower Third of Ureter
    InterventionTamsulosin Oral Capsule
    PhasePhase 4
    Registry statusCompleted

  • Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation

    NCT07113145 · start 2024-06-01

    Registered record
    Registry ID
    NCT07113145
    Conditions
    Premature (Early) Ejaculation
    Interventions
    Oral intake of medication; Oral intake of medication; Oral intake of medication; Oral intake of medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-06-01
    Completion
    2025-03-01
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremature (Early) Ejaculation
    InterventionOral intake of medication; Oral intake of medication; Oral intake of medication; Oral intake of medication
    PhasePhase 4
    Registry statusCompleted

  • On-demand Silodosin 4mg vs Dapoxetine 60mg in Treatment of Primary Premature Ejaculation

    NCT07081659 · start 2024-03-01

    Registered record
    Registry ID
    NCT07081659
    Conditions
    Premature (Early) Ejaculation
    Interventions
    sildosin 4mg; dapoxetine 60mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2024-03-01
    Completion
    2025-04-01
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremature (Early) Ejaculation
    Interventionsildosin 4mg; dapoxetine 60mg
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Silodosin vs Placebo in the Treatment of Female LUTS

    NCT06114979 · start 2023-11-01

    Registered record
    Registry ID
    NCT06114979
    Conditions
    Lower Urinary Tract Symptoms
    Interventions
    Silodosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-11-01
    Completion
    2024-12-30
    Enrolment
    278

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLower Urinary Tract Symptoms
    InterventionSilodosin; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Comparative Study for Medical Therapy for Lower Ureteral Stones

    NCT06707181 · start 2023-11-01

    Registered record
    Registry ID
    NCT06707181
    Conditions
    Lower Ureteral Stones
    Interventions
    • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-11-01
    Completion
    2024-08-18
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLower Ureteral Stones
    Intervention• The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf
    PhasePhase 3
    Registry statusCompleted